Timolol: long-term Canadian multicentre study.

This paper reports a 200-week-long study of the efficacy of timolol maleate ophthalmic preparations. At centres across Canada 117 patients were studied according to a rigid protocol. Timolol maleate was shown to be an effective antiglaucomatous drug, maintaining the intraocular pressure below 22 mm Hg throughout the study in 137 (60%) of the 227 eyes. No clinically significant effect on the pulse rate or the mean perfusion pressure was demonstrated, and the medication was well tolerated, causing few side effects or adverse reactions.